Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 3/20 | 0.50 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.30 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079678 | 0.97 | — | — | |
| Bromide SCHEMBL1086848 | 0.94 | CRBN (0.50) | CRBNMAP3K14CYP19A1BRD4CREBBP | |
| SCHEMBL14275860 | 0.79 | CRBN (0.46) | CRBNMAP3K14 | |
| Trifluoroacetic Acid SCHEMBL451826 | 0.78 | CRBN (0.37) | CRBNMAP3K14 | |
| Hydrochloric Acid SCHEMBL14738630 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL1695525 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL19359380 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL1583894 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL22659777 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL17873779 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111228-B2 | Process for the preparation of pomalidomide and its purification | NATCO PHARMA LIMITED (IN) | 2021-09-07 | — | — | US | claimed |
| US-20190233389-A1 | PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION | NATCO PHARMA LIMITED (IN) | 2019-08-01 | — | — | US | claimed |
| WO-2017221261-A1 | PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION | NATCO PHARMA LIMITED (IN) | 2017-12-28 | — | — | WO | claimed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4188373-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | Captor Therapeutics S.A. (PL) | 2023-06-07 | — | — | EP | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-8785644-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2380887-B1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORP (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-1907373-B1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2380887-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | Celgene Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110224440-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7994327-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1907373-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007005972-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004920-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION AN ORGNIZATION OF THE STATE NEW JERSEY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224440-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | CRBN 3082/4885CYP19A1 809/4885MAP3K14 1837/4885 |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | MMP2, PSME2, PSME1 | CRBN 251/4885CYP19A1 1613/4885MAP3K14 3175/4885 |
| US-20190233389-A1 | PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION | TNF, HEXD, QDPR | CRBN 1528/4885CYP19A1 3186/4885MAP3K14 898/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | CRBN 158/4885CYP19A1 3900/4885MAP3K14 4655/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | CRBN 1/4885CYP19A1 4614/4885MAP3K14 2159/4885 |
| US-11111228-B2 | Process for the preparation of pomalidomide and its purification | TNF, QDPR, HEXD | CRBN 1511/4885CYP19A1 3109/4885MAP3K14 917/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | CRBN 2/4885CYP19A1 4649/4885MAP3K14 2528/4885 |
| US-20070004920-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | TNF, DHPS, IL1A | CRBN 3387/4885CYP19A1 1586/4885MAP3K14 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.